SAE Media Group is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference on the 9th-10th of April 2018. The Antibody-drug Conjugates market is expected to reach USD 30 Billion by 2023*. http://bit.ly/2hxLtOS

Antibodies and antibody drug conjugates (ADCs) have the potential to make a groundbreaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens. 

Key topics that will be covered in the upcoming event include: fragment drug conjugates, ADC payloads, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations.

Hear from some of the best minds in the industry and partake in valuable discussion with key leaders within the field at this topical and timely event!

  • There have been massive strides within the field since the last event in 2016 - get the latest update on the progress being made and the developments within the ADC industry from people at the forefront of the field
  • Presentations of clinical data from Phase I, II and III trials as case study examples of successes and short-falls of ADCs
  • Hear about cutting edge combination therapies for onco-immunological therapies and their potential for making therapeutic strides
  • Network with a range of industry and academic specialists and key vendors, from across the field

Key Job Titles include:

Research & Development Directors/Managers/Scientists
Senior Scientists
Chief Scientific Officers
Chief Medical Officers
Heads of Clinical Development
Heads of Pre-Clinical Development
Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.

Abzena | ADC Biotechnology | Antikor Biopharma Ltd. | AS-Tec Chemicals Ltd | AstraZeneca | Bayer Schering | Cancer Research Technology Ltd | Cancer Research UK | CARBOGEN AMCIS AG | Cfm Oskar Tropitzsch e.K. | Clarivate Analytics | Crescendo Biologics Ltd | Endocyte, Inc. | Heraeus Precious Metals GmbH & Co. KG | Immunogen | King's College London | Lonza Ag | Medimmune | MedImmune Inc | Menarini Ricerche | Merrimack Pharmaceuticals Inc | MRC Technology | NBE Therapeutics | Novartis Biologics | Novasep | Oncotec Pharma Produktion GmbH | Pfizer | Piramal Pharma Solutions | Roche Pharmaceuticals | Sigma-Tau Industrie Farmaceutiche Rimile SpA | SKAN AG | Syndivia | Takeda Pharmaceuticals | The University of Bath | University College London

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Philip Howard

Philip Howard, Chief Scientific Officer, Spirogen
View Bio

9:10 Use of modelling and simulation to compare new generation HER-2 ADCs with Kadcyla™: a focus on PK and efficacy

Alison Betts

Alison Betts, ADC Scientist, Pfizer

  • Kadcyla is a HER-2 ADC approved in 2013 for patients with HER2+ metastatic breast cancer
  • Kadcyla is only efficacious in high HER2 tumors and patients are acquiring resistance
  • New generation HER-2 ADCs are being designed to overcome these limitations
  • PK/PD  methodologies for efficacy and safety differentiation will be presented
  • For PK predictions a mechanistic target mediated drug disposition model is proposed accounting for binding to shed HER-2 extracellular domain and variability across patients
  • 9:50 Application of a PK-PD Modeling & Simulation in Antibody-Drug Conjugate Development

    Aman Singh

    Aman Singh, PK-PD Scientist, Janssen

  • Preclinical to clinical translation
  • Bystander effect of ADCs
  • Binding site barrier of ADCs
  • Cell-level pharmacokinetics of ADCs
  • 10:30 Morning Coffee

    11:00 GlycoConnect™ and HydraSpace™ technologies for superior Antibody-Drug Conjugates

    Sander van Berkel

    Sander van Berkel, Director R&D Operations, Synaffix

  • Head-to-head comparison demonstrates superiority of Glycan-Conjugated ADCs (GlycoConnect™) versus mainstream technologies 
  • Readily adaptable HydraSpace™ enables highly hydrophobic payloads, dual warhead ADCs and further expands TI
  • Decomposition of Parameters Contributing to the Improved Therapeutic Index
  • GlycoConnect™ and HydraSpace™
  • 11:40 Antibody Targeted Amanitin Conjugates (ATACs) - Expanding the ADC landscape with a new payload targeting RNA Polymerase II

    Andreas Pahl

    Andreas Pahl, CSO, Heidelberg Pharma

  • Antigen-Targeted Amanitin-Conjugates (ATACs) represent a new class of ADCs using the payload Amanitin.
  • This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II.
  • The technology platform includes Amanitin supply, site-specific conjugation, demonstrated safety profile and biomarker.
  • HDP-101 is the first ATAC directed against BCMA entering Phase I trials by the end of 2018
  • 12:20 Networking Lunch

    13:30 Minor-Groove binding DNA-interactive molecules as ADC Payloads - the impact of sequence-selectivity and mono-alkylation versus cross-linking

    David E. Thurston

    David E. Thurston, Professor of Drug Discovery, King's College London

  • The impact of mono-alkylation versus intra- and interstrand cross-linking mechanisms of action on the in vitro and in vivo efficacy and toxicity of ADC payloads and ADCs.
  • Is there an opportunity to match the sequence-selectivity of DNA-interactive payloads to the genetic profiles of tumour types?
  • Is there an opportunity to improve the therapeutic window of ADCs by “tuning” the mechanism of action and sequence-selectivity of the payload?
  • 14:10 PBDs – update on an efficient and effective payload class

    Arnaud Tiberghien

    Arnaud Tiberghien, Scientist II, Chemistry, Spirogen

  • A potent and flexible class of ADC payloads and their industrial processing viability.
  • Whether or not PBDs make better payloads than others.
  • Comparison of PBD DNA crosslinkers and PBD DNA alkylators
  • New PBD payloads in developments. Consequences on mode of action, efficacy and tolerability
  • 14:50 Afternoon Tea

    15:20 Novasep’s integrated solutions for ADCs

    Francois D'Hooge

    Francois D'Hooge, Head of Bioconjugation, Novasep S A S

  • Simplifying the supply chain through an integrated offer
  • Design considerations of a dedicated conjugation facility
  • Novasep’s strengths for ADCs: case studies
  • 16:00 Precision cancer therapy ADCs with novel target, antibody and cancer toxin technologies

    Robert Boyd

    Robert Boyd, UK Site Head and Scientific Director, Oxford BioTherapeutics

  • Selection of novel ADC cancer targets in the post-genomics era
  • Improved efficacy by optimizing targets to ADC technologies
  • Target Selection criteria - how to choose the best target for your specific need
  • 16:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific and Operating Officer, Antikor Biopharma Ltd.

    9:10 Antibody-Pyrrolobenzodiazepine Conjugates

    Philip Howard

    Philip Howard, Chief Scientific Officer, Spirogen
    View Bio

  • An overview of the PBB ADC Clinical landscape
  • Present 3 case studies on PBD-ADCs for haematological indications
  • Present 1 case study on a PBD-ADC in a solid indication
  • Case studies will include both clinical and preclinical data

    9:50 Site-selective ADCs by disulfide bridging

    James Baker

    James Baker, Chemistry Lecturer, University College London

  • Site-selective ADCs offer the prospect of improved Therapeutic Indexes over traditional heterogeneous conjugation approaches, and are likely to form the basis of next generation ADCs.
  • Can achieve such site-selectivity by targeting the four interchain disulfide bonds (in IgG1s), using bridging reagents which reconnect the two cysteine residues.
  • We describe the development of Next Generation Maleimide reagents, and the related Pyridazinediones, as optimised platforms for ADCs constructed in this way.
  • 10:30 Morning Coffee

    11:00 Antibody Fragment Drug Conjugates (FDCs): A tailored therapy for solid tumours

    Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific and Operating Officer, Antikor Biopharma Ltd.

  • Discovery of antibody fragments specifically designed for FDCs
  • Manufacture of FDCs and payload screening
  • In vivo pharmacokinetics and tumour cure efficacy in gastric cancer models
  • Rodent models for toxicology and tolerability
  • 11:40 Design principles for maximizing the drug delivery efficiency and therapeutic index of ADCs

    Robert Lyon

    Robert Lyon, Senior Director Protein Sciences, Seattle Genetics Ltd

  • The conjugation of drug-linkers to an antibody can result in increased nonspecific uptake and catabolism in healthy tissues
  • This phenomenon has two potential negative consequences—unintended delivery of the drug to non-target tissues, and diminished exposure of the tumor to the ADC
  • Careful design of the drug-linker can minimize this effect in preclinical models, with demonstrable decreases in drug concentrations in normal tissues paired with maximal delivery to the tumor
  • Toxicology and xenograft studies indicate that the optimized design both decreases off-target toxicity and improves antitumor activity, and we are currently planning to evaluate this design clinically with an anti-CD48 antibody for patients with multiple myeloma
  • 12:20 Networking Lunch

    13:30 Highly Potent APIs (HPAPIs) in ADC projects

    Justin Mason-Home

    Justin Mason-Home, Director, HPAPI Project Services Limited

  • ADC Toxicants in the context of Pharma HPAPIs
  • Other ADC Component Hazards
  • Health and Safety Project Elements in Designing and Delivering HPAPI Projects
  • Risk Assessment, Risk Communication and Risk Management
  • 14:10 Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions

    Roger Beerli

    Roger Beerli, CSO, NBE Therapeutics

  • Site-specific conjugation using sortase enzyme (SMAC™-Technology), yielding homogenous ADCs.
  • Highly potent payload, providing access to difficult-to-address targets.
  • Anthracycline-based payload with attractive IO properties.
  • 14:50 Afternoon Tea

    15:20 The use of Nanobody formatting to improve immune-oncology therapeutics

    Carlo Boutton

    Carlo Boutton, Director of Technology, Ablynx

  • Small Nanobodies® with their modular design are a perfect starting point for generating multivalent and multispecific therapeutics for immune modulation.
  • The power of the platform and its flexibility to develop optimal drug formats will be demonstrated by a multivalent approach for an agonistic Nanobody against the co-stimulatory immune checkpoint receptor GITR and a multispecific T-cell recruitment format.
  • 16:00 The use of bispecific antibodies to modulate anti-tumour immune responses

    Delphine Buffet

    Delphine Buffet, Senior Research Associate, F-star

  • Bispecific antibodies: an attractive alternative to cancer treatments combinations
  • F-star’s approach to create bispecific mAb²
  • In vitro and in vivo efficacy of F-star bispecific antibodies targeting oncology pathways
  • 16:40 Chairman’s Closing Remarks and Close of Day Two


    Official Media Partner



    ADCs from early development into first-in-human studies

    ADCs from early development into first-in-human studies

    Copthorne Tara Hotel
    11th April 2018
    London, United Kingdom

    Recombinant Antibodies – structure, function and drug development

    Recombinant Antibodies – structure, function and drug development

    Copthorne Tara Hotel
    11th April 2018
    London, United Kingdom


    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.


    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.

    [SPEAKER INTERVIEW] - Robert Lyon, Senior Director Protein Sciences, Seattle Genetics




    [SPEAKER INTERVIEW] - Mahendra Deonarain, Chief Executive and Scientific Officer, Antikor Biopharma




    [2016 PRESENTATION] - NBE Therapeutics


    [SPEAKER INTERVIEW] - Alison Betts, Associate Research Fellow, Pfizer


    Media Partners

    ADC Review

    Official Media Partner

    ADC Review / Journal of Antibody-drug Conjugates (ISSN: 2327-0152) is an international publication combining professional social media with an online-only, hybrid open-access, peer reviewed journal. The Journal aims to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. Key information includes peer-reviewed articles, news features, discussions, blogs, and a knowledge center offering the latest and most relevant information about Antibody Drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.

    Media Partners

    Pharma Marketing




    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.



    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!

    Pharmaceutical Technology


    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

    Medical Device Network


    Medicaldevice-network.com is your one stop for information on the medical device industry, covering everything along the supply chain from biomaterials and materials solutions to electronics, packaging, motors and motion control, outsourcing and more. Through our international team of journalists, we cover diagnosis, prevention, monitoring, standards, treatment and technology – all you need as a professional in the medical industry to stay abreast of the latest developments in your field.



    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.

    Journal for Clinical Studies – Your Resource for Multisite Studies & Emerging Markets


    Published bi-monthly.JCS is a unique journal, dedicated to providing information to the global pharmaceutical, biotechnology, medical devices and contract research organisations. JCS details practical and theoretical operational procedures, challenges, validatory and regulatory guidelines when conducting trials on a multisite basis and particularly within the emerging markets, naïve patient population, and remote access areas. JCS provides country by country objectives and uniquely brings you experiences in therapeutic areas of Liver diseases, kidney diseases, insect borne diseases, malnutrition and under nutrition. JCS is led by a strong editorial advisory board sourced out for their experiences; you will get the most practical insight for your global studies. JCS invites you to join us, write for us, feature your experiences with us, advertise your capabilities with us, and ask our advisory board for suggestions and guidelines. Let us make health care available to all.

    Swiss Biotech Association


    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

    Drug Target Review


    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.



    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!



    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.

    International Pharmaceutical Industry


    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.

    Technology Networks


    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

    World Pharma News


    Drug Discovery Today


    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.



    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.



    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    Pharma Journalist


    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

    Inderscience Publishers


    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.



    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.



    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com



    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

    Select Science


    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.




    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out